SCHEMBL2052014

SCHEMBL2052014

CCCS(=O)(=O)N1CCC(c2c(C)cccc2C(N)=O)CC1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 2/20 0.51
CHUK O15111 2/20 0.51
AURKA O14965 1/20 0.51
FLT3 P36888 1/20 0.51
CSNK1E P49674 1/20 0.51
BTK Q06187 1/20 0.51
USP2 O75604 1/20 0.45
LMNA P02545 2/20 0.44
SLC6A9 P48067 2/20 0.44
HTR1A P08908 3/20 0.43
GAA P10253 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
PKM P14618 1/20 0.43
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2052016 0.84 IKBKB (0.56) IKBKBCHUKAURKAFLT3CSNK1E
SCHEMBL3840452 0.78 CXCR5 (0.45) LMNAHTR1AKDM4EALDH1A1
SCHEMBL4359667 0.75 CXCR5 (0.52) HTR1AMEN1KMT2AKDM4EALDH1A1
SCHEMBL4141784 0.74 CXCR5 (0.51) HTR1AMEN1KMT2AKDM4EALDH1A1
SCHEMBL31074260 0.74 CXCR5 (0.51) HTR1AMEN1KMT2AKDM4EALDH1A1
SCHEMBL17786108 0.72 PARP1 (0.44) LMNAMEN1KMT2AALDH1A1
SCHEMBL20822489 0.72 CYP11B1 (0.42) LMNAHTR1ASMN1; SMN2KDM4EALDH1A1
SCHEMBL3809365 0.72 PARP1 (0.51) IKBKBCHUKAURKA
SCHEMBL10326073 0.70 HSD11B1 (0.46) BTKMEN1KMT2AALDH1A1
SCHEMBL5136169 0.70 NAMPT (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2328576-A1 USE OF NMDA ACTIVITY ENHANCERS TO TREAT HYPERSOMNIA, REDUCED WAKEFULNESS OR REDUCED VIGILANCE Merck Sharp & Dohme Limited (GB) 2011-06-08 EP disclosed
WO-2010035026-A1 USE OF NMDA ACTIVITY ENHANCERS TO TREAT HYPERSOMNIA, REDUCED WAKEFULNESS OR REDUCED VIGILANCE MERCK SHARP & DOHME LTD (GB) 2010-04-01 WO disclosed